Osteoarthritis improvement effect of Chrysanthemum zawadskii var. latilobum extract in relation to genotype
Abstract
Abstract:Objectives: To determine whether SNPs of osteoarthritis (OA)-related genes predict the effect of Chrysanthemum zawadskii var. latilobum (CZ) extract in OA patients with OA. Subjects/methods: To analyze correlations between CZ extract effects in humans and their genotypes, 121 Korean patients with OA were recruited. Patients ingested 600 mg/day of the CZ extract GCWB106 (one tablet daily), including 250-mg CZ, or placebo (one tablet daily) for 12 weeks. Twenty SNPs were genotyped in 11 genes associated with OA pathogenesis, including tumor necrosis factor-alpha (TNF-α) and matrix metalloproteinases (MMPs), and 9 genes involved in OA-related dietary intervention. The Visual Analogue Scale (VAS) and Korean Western Ontario and McMaster Universities (K-WOMAC) were measured as indicators of GCWB106 effect. Statistical comparisons were performed using Kruskal-Wallis tests to identify associations between these scales and genotyped loci in patients with OA. Results: Three SNPs (PPARG rs3856806, MMP13 rs2252070, and ZIP2 rs2234632) were significantly associated with the degree of change in VAS pain score. Homozygous CC genotype carriers of rs3856806, G allele carriers (GA or GG) of rs2252070, and T allele carriers (GT or TT) of rs2234632 showed lower VAS score (i.e., less severe symptoms) in the GCWB106 group (n=53) than the placebo group (n=57) (p=0.026, p=0.009, and p=0.025, respectively). Gene–gene interaction effects on GCWB106-mediated pain relief were then examined, and it was found that the addition of each genotype resulted in a greater decrease in VAS pain score in the GCWB106 group (p=0.0024) but not the placebo group (p=0.7734). Conclusions: These novel predictive markers for the pain-relieving effects of GCWB106 may be used in the personalized treatment of patients with OA.
References
1 . Osteoarthritis of the knee. Acta Orthop Belg. 1961;27:372–3.
2 . The role of inflammatory and anti-inflammatory cytokines in the pathogenesis of osteoarthritis. Mediators Inflamm. 2014;2014.
3 . Mechanism of cartilage destruction in osteoarthritis. Nagoya J Med Sci. 2002;65(3–4):73–84.
4 . Cartilage and bone destruction in arthritis: pathogenesis and treatment strategy: A literature review. Cells. 2019;8(8).
5 . Metalloproteinases: Their role in arthritis and potential as therapeutic targets. Expert Opin Ther Targets. 2003;7(1):19–34.
6 . Matrix metalloproteinases: a tail of a frog that became a prince. Nat Rev Mol cell Biol. 2002;3(March).
7 Matrix metalloproteinases in arthritic disease. Arthritis Res. 2002;4:S39–49.
8 . New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002;2(3):161–74.
9 . Biochemical characterization of human collagenase-3. J Biol Chem. 1996;271(3):1544–50.
10 The role of the C-terminal domain of human collagenase-3 (MMP13) in the activation of procollagenase-3, substrate specificity, and tissue inhibitor of metalloproteinase interaction. J Biol Chem. 1997;272(12):7608–16.
11 Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage. J Clin Invest. 1996;97(3):761–8.
12 p16INK4a and its regulator miR-24 link senescence and chondrocyte terminal differentiation-associated matrix remodeling in osteoarthritis. Arthritis Res Ther. 2014;16:R58.
13 . New insights on the MMP13 regulatory network in the pathogenesis of early osteoarthritis. Arthritis Res Ther. 2017;19(1):1–12.
14 . Risk factors and burden of osteoarthritis. Ann Phys Rehabil Med. 2016;59(3):134–8.
15 . Knee osteoarthritis prevalence, risk factors, pathogenesis and features: Part I. Casp J Intern Med. 2011;2(2):205–12.
16 . A comprehensive review of non-steroidal anti-inflammatory drug use in the elderly. Aging Dis. 2018;9(1):143–50.
17 Protective effect of linarin against d-galactosamine and lipopolysaccharide-induced fulminant hepatic failure. Eur J Pharmacol. 2014;738:66–73.
18 Inhibitory activity of Chrysanthemi sibirici herba extract on RBL-2H3 mast cells and compound 48/80-induced anaphylaxis. J Ethnopharmacol. 2004;95(2–3):425–30.
19 Anti-inflammatory activity of Chrysanthemum zawadskii var. latilobum leaf extract through haem oxygenase-1 induction. J Funct Foods. 2012;4(2):474–9.
20 Inhibitory effect of Chrysanthemum zawadskii Herbich var. latilobum Kitamura extract on RANKL-induced osteoclast differentiation. Evid Based Complement Altern Med. 2013;2013:1–11.
21 The extract of Chrysanthemum zawadskii var. latilobum ameliorates collagen-induced arthritis in mice. Evid Based Complement Altern Med. 2016;2016.
22 BST106 protects against cartilage damage by inhibition of apoptosis and enhancement of autophagy in osteoarthritic rats. Biol Pharm Bull. 2018;41(8):1257–68.
23 . Anti-osteoarthritic mechanisms of chrysanthemum osteoarthritic rats and interleukin-1β-induced SW1353 human chondrocytes. Med. 2020;56(12):685.
24 . Efficacy of GCWB106 (Chrysanthemum zawadskii var. latilobum extract) in osteoarthritis of the knee: A 12-week randomized, double-blind, placebo-controlled study. Medicine (Baltimore). 2021;100(26):e26542.
25 MMP13 is a critical target gene during the progression of osteoarthritis. Arthritis Res Ther. 2013;15(1):R5.
26 Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. J Clin Invest. 1997;99(7):1534–45.
27 . Update on zinc biology. Ann Nutr Metab. 2013;62(SUPPL. 1):8–17.
28 . Relative messenger RNA expression profiling of collagenases and aggrecanases in human articular chondrocytes in vivo and in vitro. Arthritis Rheum. 2002;46(10):2648–57.
29 Associations between knee structural measures, circulating inflammatory factors and MMP13 in patients with knee osteoarthritis. Osteoarthr Cartil. 2018;26(8):1063–9.
30 . Association of IL-6, IL-8, MMP13 gene polymorphisms with knee osteoarthritis susceptibility in the Chinese Han population. Biosci Rep. 2019;39(2):1–9.
31 Regulation of the catabolic cascade in osteoarthritis by the zinc-ZIP8-MTF1 axis. Cell. 2014;156(4):730–43.
32 . Cell biology: Protein kinase CK2 triggers cytosolic zinc signaling pathways by phosphorylation of zinc channel ZIP7. Sci Signal. 2012;5(210):1–10.
33 The requirement of zinc and calcium ions for functional MMP activity in demineralized dentin matrices. Dent Mater. 2010;26(11):1059–67.
34 . Zinc as a therapeutic agent in bone regeneration. Materials (Basel). 2020;13(10):1–22.
35 Differences in zinc status between patients with osteoarthritis and osteoporosis. J Trace Elem Med Biol. 2009;23(1):1–8.
36 A novel Zip2 Gln/Arg/Leu codon 2 polymorphism is associated with carotid artery disease in aging. Rejuvenation Res. 2008;11(2):297–300.
37 Effect of ZIP2 Gln/Arg/Leu (rs2234632) polymorphism on zinc homeostasis and inflammatory response following zinc supplementation. BioFactors. 2015;41(6):414–23.
38 . RANTES/CCL5 induces collagen degradation by activating MMP-1 and MMP13 expression in human rheumatoid arthritis synovial fibroblasts. Front Immunol. 2017;8(OCT):1–12.
39 . The nuclear receptor PPARγ – Bigger than fat. Curr Opin Genet Dev. 1998;8(5):576–81.
40 The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature. 1998;391:79–82.
41 . PPAR-γ agonists inhibit production of monocyte inflammatory cytokine. Nature. 1998;391(January):82–6.
42 Enhanced and coordinated in vivo expression of inflammatory cytokines and nitric oxide synthase by chondrocytes from patients with osteoarthritis. Arthritis Rheum. 1998;41(12):2165–74.
43 Can altered production of interleukin-1β, interleukin-6, transforming growth factor-β and prostaglandin E2 by isolated human subchondral osteoblasts identity two subgroups of osteoarthritic patients. Osteoarthr Cartil. 2002;10(6):491–500.
44 . Cytokine expression in synovial membranes of patients with rheumatoid arthritis and osteoarthritis. Ann Rheum Dis. 1993;52(12):870–5.
45 Plasma proteins present in osteoarthritic synovial fluid can stimulate cytokine production via Toll-like receptor 4. Arthritis Res Ther. 2012;14(1):1–13.
46 PPARγ insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Invest. 2004;113(6):846–55.
47 Peroxisome proliferator-activated receptor γ1 expression is diminished in human osteoarthritic cartilage and is downregulated by interleukin-1β in articular chondrocytes. Arthritis Res Ther. 2007;9(2):1–11.
48 PPARγ deficiency results in severe, accelerated osteoarthritis associated with aberrant mTOR signalling in the articular cartilage. Ann Rheum Dis. 2015;74(3):569–78.
49 PPARγ gene C161T substitution is associated with reduced risk of coronary artery disease and decreased proinflammatory cytokine expression. Am Heart J. 2007;154(4):718–24.
50 The association of Pro12Ala polymorphism of peroxisome proliferator-activated receptor-γ gene with serum osteoprotegerin levels in healthy Korean women. Exp Mol Med. 2007;39(6):696–704.
51 The effects of C161→T polymorphisms in exon 6 of peroxisome proliferator-activated receptor-γ gene on bone mineral metabolism and serum osteoprotegerin levels in healthy middle-aged women. Am J Obstet Gynecol. 2005;192(4):1087–93.
52 Osteoprotegerin reduces the development of pain behaviour and joint pathology in a model of osteoarthritis. Ann Rheum Dis. 2014;73(8):1558–65.
